The ACE-Pan tumor-01 trial, performed in HER2-positive solid tumors in the US and Australia, achieved an ORR of 67% (two out of three breast cancer patients) [41], and the ACE-Breast-01 trial, performed in HER2-positive breast cancers in China, achieved an ORR of 74% (14 out of 19 patients) [42]. Here, ERBB2 is linked to breast carcinoma.